Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine

M, Abdul Wajid; Gupta, Aditya; Das, Gargi; Meena, Jagdish Prasad; Seth, Rachna

doi:10.1080/08880018.2020.1767244

Cited by 9 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some patients with JMML have partially responded to 6MP with or without low-dose cytarabine. 15 Moreover, those with germline mutations of NRAS , KRAS , or PTPN 11 and others with CBL mutations can experience spontaneous clinical remission if the disease behaves as a transient polyclonal MPD, as previously reported. 7 Using rapid exome sequencing, we identified a germline mutation of NRAS in our patient, a finding which prompted more conservative management with 6MP for hematologic stabilization.…”

Section: Discussionmentioning

confidence: 99%

Leukocytosis and Splenomegaly in a Neonate With NRAS Mutation

Lucena

Balasundaram

Carney

et al. 2023

Clin Pediatr (Phila)

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Leukocytosis and Splenomegaly in a Neonate With NRAS Mutation

Lucena

Balasundaram

Carney

et al. 2023

Clin Pediatr (Phila)

View full text Add to dashboard Cite

“…The advantages of this approach include low cost, outpatient management and decreased requirement of blood components. In a subset of patients, it may provide a remission [17].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of hypomethylating therapy prior to allogeneic hematopoietic stem cell transplantation upon clinical outcomes in patients with juvenile myelomonocytic leukemia

Osipova,

Tsvetkova,

Paina

et al. 2023

CTT

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for patients with juvenile myelomonocytic leukemia (JMML). The optimal pre-transplantation therapy with maximum efficacy and minimal toxic complications remains a matter of debate. This retrospective study demonstrates single center experience of pre-transplant therapy by hypomethylating agent in children with JMML. Overall, 33 patients were included in analysis. Improved outcome was observed in patients that received pre-transplant AML-like therapy+hypomethylating agents (HMA), AML-like therapy, low-dose chemotherapy ±HMA, only HMA (OS=83%, 44%, 43%, 0%). We have demonstrated that loss of heterozygosity (LoH) of HLA is an important determinant of sensitivity to adoptive immunotherapy and indication for second allo-HSCT.

show abstract